FDA Approval: Giredestrant (Wilserdly) with Everolimus for ER-positive, HER2-negative, ESR1-mutated Locally Advanced or Metastatic Breast Cancer image

FDA Approval: Giredestrant (Wilserdly) with Everolimus for ER-positive, HER2-negative, ESR1-mutated Locally Advanced or Metastatic Breast Cancer

By Jimena Vicencio, MD Jimena is a medical doctor currently studying a bachelor in journalism. Posted on: Nov 18, 2026 Medically reviewed on: Nov 18, 2026

On November 16, 2026, the U.S. Food and Drug Administration (FDA) approved a new hormone therapy called giredestrant (Wilserdly, Roche) in combination with everolimus for some people with advanced breast cancer. It is approved for people whose breast cancer meets these criteria: 

  • Estrogen receptor-positive (ER+)

  • Human epidermal growth factor receptor 2-negative (HER2-)

  • Has estrogen receptor 1 mutations (ESR1-mutated)

  • Locally advanced or metastatic 

  • Has recurred during or after endocrine-based adjuvant therapy or has progressed on at least one endocrine-based treatment in the metastatic setting

In the United States, an estimated 321,910 people will be diagnosed with breast cancer in 2026. The most common type of breast cancer is hormone receptor-positive/HER2-negative. Over the course of treatment, around 40% of patients will develop ESR1 mutations. These mutations make it harder for endocrine therapies to successfully control the cancer and can drive disease progression. This treatment combination helps minimize the effect of this mutation. 

“Patients with advanced breast cancer progressing on endocrine therapies often face difficult choices and deteriorating quality of life as options narrow. The evERA trial demonstrates that the oral giredestrant combination regimen directly targets the primary genomic drivers of resistance, offering patients prolonged disease control through a fully oral therapeutic option,” said Dr. Erica L. Mayer of Dana-Farber Cancer Institute in a press release about the approval.

How does giredestrant and everolimus treat ER+/HER2- ESR1-mutated advanced breast cancer?

Giredestrant is a hormone therapy called a selective estrogen receptor degrader (SERD). It binds to estrogen receptors, by doing this, the estrogen is blocked, and the cancer that is fueled by estrogens, can stop growing. 

Everolimus is a targeted therapy. It also helps stop cancer cell growth. 

evERA Breast Cancer: The study that led to the everolimus approval

This approval was based on the phase 3 evERA Breast Cancer clinical trial. It included 373 adults with ER+, HER2- locally advanced or metastatic breast cancer. Of those, 201 had ESR1 mutations. Patients received either giredestrant or another endocrine therapy. Both groups also received everolimus. Patients who had not yet started menopause or were transitioning to menopause and male patients also received a GnRH agonist to stop ovarian function. Treatment continued until the cancer grew or changed or side effect toxicity. 

There was a statistically significant improvement in progression free survival for patients treated with giredestrant. Patients with ESR1 mutations treated with giredestrant had a 62% lower risk of disease progression than those treated with another endocrine therapy. The median progression free survival was 10 months in the giredestrant group and 5.5 months in the group treated with another endocrine therapy. Researchers are still studying the overall survival benefit.  

What are the common side effects of giredestrant and everolimus?

The most common side effects of giredestrant with everolimus were: 

  • Mouth sores and inflammation

  • Rash

  • Fatigue

  • Diarrhea

  • Muscle and bone pain

  • Lung inflammation

  • Nausea

Questions to ask your care team about giredestrant and everolimus

If you or a loved one has ER+/HER2- advanced breast cancer with ESR1 mutations, ask your healthcare team about giredestrant or ongoing clinical trials. Consider asking your care team the following questions: 

  • Am I eligible for treatment with giredestrant and everolimus based on my biomarkers and treatment history?

  • Do I have ESR1-mutated breast cancer?

  • How does this treatment compare to other options available to me?

  • What side effects should I be aware of?

SOURCES: